Titan Pharmaceuticals, Inc. (NASDAQ:TTNP – Get Rating) was the target of a large decline in short interest in April. As of April 30th, there was short interest totalling 188,300 shares, a decline of 40.9% from the April 15th total of 318,400 shares. Based on an average daily trading volume, of 162,300 shares, the days-to-cover ratio is currently 1.2 days.
Shares of TTNP opened at $0.57 on Friday. The stock has a fifty day moving average price of $0.85 and a two-hundred day moving average price of $1.11. Titan Pharmaceuticals has a 52-week low of $0.49 and a 52-week high of $3.10.
Separately, StockNews.com initiated coverage on Titan Pharmaceuticals in a research note on Friday. They issued a “hold” rating on the stock.
Titan Pharmaceuticals Company Profile (Get Rating)
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union.
- Get a free copy of the StockNews.com research report on Titan Pharmaceuticals (TTNP)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.